Selected article for: "control group and exact test"

Author: Leong, Hoe‐Nam; Ang, Brenda; Earnest, Arul; Teoh, Cindy; Xu, Wei; Leo, Yee‐Sin
Title: Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003
  • Cord-id: 7dafsxp9
  • Document date: 2004_8_10
  • ID: 7dafsxp9
    Snippet: Objective Ribavirin is a broad spectrum nucleoside analogue efficacious in the treatment of several viral infections. In the recent severe acute respiratory syndrome (SARS) outbreak, ribavirin was used in various countries against this novel coronavirus. We conducted a retrospective analysis to assess the efficacy of ribavirin in the treatment of SARS in Singapore. Methods A total of 229 cases were analysed. Ninety‐seven (42.4%) patients received ribavirin at a mean of 6.4 days of illness. Cli
    Document: Objective Ribavirin is a broad spectrum nucleoside analogue efficacious in the treatment of several viral infections. In the recent severe acute respiratory syndrome (SARS) outbreak, ribavirin was used in various countries against this novel coronavirus. We conducted a retrospective analysis to assess the efficacy of ribavirin in the treatment of SARS in Singapore. Methods A total of 229 cases were analysed. Ninety‐seven (42.4%) patients received ribavirin at a mean of 6.4 days of illness. Clinical and laboratory parameters taken at the start of ribavirin treatment were compared with day 5, 6 or 7 parameters of those patients not on treatment. The two groups were compared using Fisher's exact test and Student's t‐test. Multivariate analysis was performed using Cox regression model with death as the outcome of interest. Results The treatment group had younger women with more symptoms of myalgia (P < 0.001). The crude death rate was 12.9% in the control and 10.3% (P = 0.679) in the treatment group. After correction for age, male sex, lactate dehydrogenase levels and steroid use, the hazard ratio was 1.03 (95% CI: 0.44–2.41, P = 0.939). Conclusion In this retrospective, uncontrolled cohort analysis, use of ribavirin did not appear to confer any benefit for patients with SARS.

    Search related documents:
    Co phrase search for related documents
    • acute illness and administration route: 1
    • acute illness and admission day: 1, 2, 3, 4, 5, 6, 7, 8
    • acute illness and loading dose: 1
    • acute illness and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute myocardial infarction and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute myocardial infarction and loading dose: 1, 2, 3, 4
    • acute period and adenovirus infection: 1, 2
    • acute period and admission day: 1
    • acute period and lung function: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and adenovirus infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory syndrome and adjusted crude: 1, 2, 3, 4, 5
    • acute respiratory syndrome and administration route: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and loading dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and low apache score: 1
    • acute respiratory syndrome and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung function patient: 1, 2, 3, 4
    • adenovirus infection and lung function: 1
    • administration route and lung function: 1, 2, 3